Rafal Dziadziuszko

17 Smoluchowskiego St
Gdansk, PM 80215, Poland

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 175 publications

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Bridging evidence and practice: international multidisciplinary consensus on non-metastatic NSCLC.

Journal: Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer

Published: May 26, 2026

SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation.

SKYSCRAPER-03: A Phase III Study of Tiragolumab Plus Atezolizumab Versus Durvalumab in Locally Advanced, Unresectable, Stage III NSCLC After Platinum-Based Concurrent Chemoradiation.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: May 08, 2026

Prognostic Role of 18F-FDG PET/CT in Oligometastatic Non-Small Cell Lung Cancer: Preliminary Results from Single Center.

Prognostic Role of 18F-FDG PET/CT in Oligometastatic Non-Small Cell Lung Cancer: Preliminary Results from Single Center.

Journal: Cancers

Published: April 22, 2026

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.

Disease characteristics and treatment outcomes in patients with resected early-stage ALK-positive non-small cell lung cancer from the randomized ALINA trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: January 16, 2026

Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.

Adjuvant Durvalumab in Completely Resected Early-Stage Non-Small Cell Lung Cancer.

Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology

Published: January 13, 2026

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

Global advances and future directions in lung cancer care: expert consensus and strategic priorities.

Journal: ESMO open

Published: November 15, 2025

Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer.

Plain language summary of the ALINA study results: alectinib compared with chemotherapy after surgery in people with ALK-positive non-small cell lung cancer.

Journal: Future science OA

Published: November 11, 2025

Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer using 18F-FDG PET/CT radiomics.

Non-invasive assessment of PD-L1 status and histology in non-small cell lung cancer using 18F-FDG PET/CT radiomics.

Journal: Journal of translational medicine

Published: November 05, 2025

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

TAPISTRY: A Phase II Study of Atezolizumab in Patients with Tumor Mutational Burden-High Tumors.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: September 12, 2025

Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.

Adjuvant alectinib versus chemotherapy in resected ALK-positive non-small-cell lung cancer (ALINA): health-related quality-of-life and safety outcomes from a randomised, open-label, phase 3 trial.

Journal: The Lancet. Oncology

Published: September 11, 2025

Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.

Novel pembrolizumab-based treatments as first-line therapy in advanced clear-cell renal cell carcinoma: substudy 03A of the open-label, umbrella platform, phase I/II KEYMAKER-U03 trial.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: September 07, 2025

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

Alectinib versus crizotinib in previously untreated ALK-positive advanced non-small cell lung cancer: final overall survival analysis of the phase III ALEX study.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: August 19, 2025

Showing 1-12 of 175

Last Updated: 09/26/2026